A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...
The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...
received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease. The European Commission is now ...
has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer's disease," the European Medicines Agency said ...
received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease. The European Commission is now ...